News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Bayer is investing over €500m ($700m) in manufacturing recombinant factor VIII (rFVIII) products citing growing demand for long-term prophylactic treatment rather than ‘on-demand’ haemophilia drugs.
The contract to design and build the UK’s £38m ($63m) National Biologics Manufacturing Centre (NBMC) has been awarded to Interserve.
Less H5N1 influenza vaccine than expected will be available in Japan this year after downstream processing problems at a plant being set up by Daiichi Sankyo.
An analyst predicts overlap between Thermo Fisher and Life Technologies will present manufacturing, procurement and logistics cost-saving opportunities.